<DOC>
	<DOCNO>NCT02342067</DOCNO>
	<brief_summary>A single center , open-label , fix sequence study evaluate pharmacokinetics ( PK ) Cenicriviroc ( CVC ) administer without Pioglitazone ( PGZ ) , evaluate PK PGZ administer without CVC .</brief_summary>
	<brief_title>Pharmacokinetic Safety Study Cenicriviroc Pioglitazone , When Dosed Alone Combination</brief_title>
	<detailed_description>This open-label , fixed-sequence , 3-period study conduct single center evaluate following : - PK CVC administer without PGZ - PK PGZ administer without CVC - Safety CVC administer without PGZ - Tolerability CVC administer without PGZ</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Provide write informed consent BMI ≥ 18 ≤ 35 kg/m2 No clinically relevant abnormality base medical history , physical examination , clinical laboratory evaluation , 12lead ECG Agree comply study procedure restriction Any disease condition might affect drug absorption , metabolism , excretion , clinically significant condition determine investigator History stomach intestinal surgery , except fully heal appendectomy and/or cholecystectomy Serum ALT , AST bilirubin ≥ grade 1 ( ALT AST &gt; ULN 3.0 x ULN ; bilirubin &gt; ULN 1.5 x ULN ) screen Positive HIV , HBV HCV infection Use prescription drug prohibit medication within 30 day first dose study medication Use alcoholcontaining caffeinecontaining food beverage within 72 hour prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>